Skip to main
INSM

Insmed (INSM) Stock Forecast & Price Target

Insmed (INSM) Analyst Ratings

Based on 18 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Insmed is expected to continue its strong momentum with the recent launch of Brinsupri and successful clinical-stage programs for respiratory and inflammatory conditions. The company's focus on technology and potential for future growth in emerging markets, coupled with their strong financial performance and diverse portfolio, make them an attractive investment opportunity for long-term growth.

Bears say

Insmed is a biopharmaceutical company with a commercial portfolio and clinical pipeline focusing on three therapeutic areas. Although the company's two commercial products have shown growth, its clinical-stage programs have yet to demonstrate significant success. The company's pre-clinical research programs show promise, but are still in early stages and may not yield successful treatments in the future. Additionally, the company faces industry-wide risks such as regulatory challenges and competition. Despite these challenges, the company has potential for long-term revenue growth with the launch of their new drug Brinsupri and a strong pipeline, which our analyst believes will drive the stock price above our $212 price target in the near term.

Insmed (INSM) has been analyzed by 18 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insmed (INSM) Forecast

Analysts have given Insmed (INSM) a Strong Buy based on their latest research and market trends.

According to 18 analysts, Insmed (INSM) has a Strong Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $209.72, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $209.72, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insmed (INSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.